Enveric Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
ENVB$1.51+4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses | ||
| General and administrative | $5,792,573 | $6,453,505 |
| Research and development | 2,781,017 | 2,841,272 |
| Depreciation and amortization | 200,858 | 337,489 |
| Total operating expenses | 8,774,448 | 9,632,266 |
| Loss from operations | (8,774,448) | (9,632,266) |
| Other income (expense) | ||
| Other income | 2,567 | 65,990 |
| Interest (expense) income, net | (106) | 219 |
| Total other income | 2,461 | 66,209 |
| Net loss before income taxes | (8,771,987) | (9,566,057) |
| Income tax expense | — | (8,930) |
| Net loss | (8,771,987) | (9,574,987) |
| Less deemed dividend on inducement of warrants | 3,359,485 | — |
| Net loss attributable to shareholders | $(12,131,472) | $(9,574,987) |
| Other comprehensive income (loss) | ||
| Foreign currency translation | 14,479 | (24,768) |
| Comprehensive loss | $(8,757,508) | $(9,599,755) |
| Net loss per share - basic and diluted | $(36.24) | $(228.48) |
| Weighted average shares outstanding, basic and diluted | 334,719 | 41,908 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.